Trial Profile

Phase III Study on the Effectiveness of OSAG 101 (Theraloc) [nimotuzumab] in Newly Diagnosed Intrinsic Pontine Gliomas of Children and Adolescents

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Sep 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nimotuzumab (Primary)
Indications Glioma
Focus Registrational; Therapeutic Use
Sponsors Oncoscience

Most Recent Events

29 Oct 2009 YM Biosciences announced in a media release, that updated results were presented by Oncoscience AG, at the 41st Annual Meeting of the International Society of Pediatric Oncology (SIOP) held in Sao Paulo, Brazil from October 5th-9th, 2009.
09 Oct 2009 Oncoscience presents results for the first time at the World's Convention for Pediatric Oncology.
30 May 2008 Tolerability results presented at 44th Annual Meeting of the American Society of Clinical Oncology (ASCO).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com